19 Harley St, London, W1G 9QJ, UK

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma

PURPOSE: This study compared denosumab, a fully human monoclonal anti-receptor activator of nuclear factor kappa-B ligand antibody, with zoledronic acid (ZA) for delaying or preventing skeletal-related events (SRE) in patients with advanced cancer and bone metastases (excluding breast and prostate) or myeloma. PATIENTS AND METHODS: Eligible patients were randomly assigned in a double-blind, double-dummy design to receive monthly subcutaneous denosumab 120 mg (n = 886) or intravenous ZA 4 mg (dose adjusted for renal impairment; n = 890). Daily supplemental calcium and vitamin D were strongly recommended. The primary end point was time to first on-study SRE (pathologic fracture, radiation or surgery to bone, or spinal cord compression). RESULTS: Denosumab was noninferior to ZA in delaying time to first on-study SRE (hazard ratio, 0.84; 95% CI, 0.71 to 0.98; P = .0007). Although directionally favorable, denosumab was not statistically superior to ZA in delaying time to first on-study SRE (P = .03 unadjusted; P = .06 adjusted for multiplicity) or time to first-and-subsequent (multiple) SRE (rate ratio, 0.90; 95% CI, 0.77 to 1.04; P = .14). Overall survival and disease progression were similar between groups. Hypocalcemia occurred more frequently with denosumab. Osteonecrosis of the jaw occurred at similarly low rates in both groups. Acute-phase reactions after the first dose occurred more frequently with ZA, as did renal adverse events and elevations in serum creatinine based on National Cancer Institute Common Toxicity Criteria for Adverse Events grading. CONCLUSION: Denosumab was noninferior (trending to superiority) to ZA in preventing or delaying first on-study SRE in patients with advanced cancer metastatic to bone or myeloma. Denosumab represents a potential novel treatment option with the convenience of subcutaneous administration and no requirement for renal monitoring or dose adjustment

Keywords : Adolescent,Adult,Aged,Aged,80 and over,Antibodies,Antibodies,Monoclonal,Antibodies,Monoclonal,Humanized,Antineoplastic Combined Chemotherapy Protocols,Bone Density,Bone Density Conservation Agents,Bone Neoplasms,Calcium,Denosumab,Diphosphonates,Disease Progression,Double-Blind Method,drug therapy,Female,Humans,Imidazoles,International Agencies,Male,methods,Middle Aged,Multiple Myeloma,Neoplasms,pathology,Rank Ligand,secondary,Spinal Cord,Spinal Cord Compression,surgery,Survival Rate,therapeutic use,toxicity,Treatment Outcome,Young Adult,Zoledronic Acid,, Doubleblind,Study,Denosumab,Versus, gildersleve

Date of Publication : 2011 Mar 20

Authors : Henry DH;Costa L;Goldwasser F;Hirsh V;Hungria V;Prausova J;Scagliotti GV;Sleeboom H;Spencer A;Vadhan-Raj S;von MR;Willenbacher W;Woll PJ;Wang J;Jiang Q;Jun S;Dansey R;Yeh H;

Organisation : Joan Karnell Cancer Center, Philadelphia, PA 19106, USA. davidhenry@pennoncology.com

Journal of Publication : J Clin Oncol

Pubmed Link : https://www.ncbi.nlm.nih.gov/pubmed/21343556

The London Spine Unit : Harley Street UK. Specialists in Cutting Edge Technologies for Spinal Surgery

Make an Appointment 

Trustpilot Reviews
Doctify Reviews
Top Doctor Reviews

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma | Levator scapulae chronic pain

What our patients say ...

Consultant Spine Surgeon
Consultant Spine Surgeon
Consultant Spine Surgeon

This surgical technique consists of a percutaneous approach for the treatment of small to medium size hernias of the intervertebral disc by laser energy. The main objective is to reduce the intradiscal pressure in the nucleus pulposus

Laser Disc Surgery can be performed under local anaesthetic as a day case at our centre on the prestigious Harley Street.
What is London spine unit and How it Works

The London Spine Unit was established in 2005 and has successfully treated over 5000 patients. All conditions are treated.

treatment of all spinal disorders

The London Spine Unit specialises in Minimally Invasive Treatments allowing rapid recovery and return to normal function

Trusted by patients worldwide

The London Spine Unit provides the highest quality care to all patients and has VIP services for those seeking exceptional services

If you have any emergency Doctor’s need, simply call our 24 hour emergency

Your personal case manager will ensure that you receive the best possible care.

Call Now 

+44 844 589 2020
+44 203 973 8810